Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25146247 | 0.94 | FAAH (0.44) | MGLLPDCD1LG2CD274ENPP2ATXN2 | |
| SCHEMBL25146284 | 0.93 | ENPP2 (0.42) | MGLLPDCD1LG2CD274ENPP2ATXN2 | |
| SCHEMBL25146037 | 0.90 | MGLL (0.45) | MGLLPDCD1LG2CD274FAAHCYP2D6 | |
| SCHEMBL30408413 | 0.86 | MGLL (0.39) | MGLLENPP2ATXN2FAAHHDAC6 | |
| SCHEMBL30409398 | 0.85 | MGLL (0.39) | MGLLPDCD1LG2CD274ENPP2ATXN2 | |
| SCHEMBL20695464 | 0.80 | MGLL (0.47) | MGLLENPP2ATXN2 | |
| SCHEMBL30409293 | 0.80 | FAAH (0.42) | MGLLENPP2ATXN2FAAHUSP2 | |
| SCHEMBL30409545 | 0.80 | MGLL (0.34) | MGLLPDCD1LG2CD274ENPP2ATXN2 | |
| SCHEMBL25146079 | 0.80 | FAAH (0.43) | ENPP2ATXN2FAAHUSP2HPGD | |
| SCHEMBL25146080 | 0.79 | MGLL (0.47) | MGLLFAAHUSP2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | claimed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | claimed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | disclosed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | MGLL 5/4885PDCD1LG2 3231/4885CD274 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.